Enzo Biochem (ENZ) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ENZ Hot Sheet
Price: $0.31 --0%
Financial Fact:
Royalty and license fee income: 300K
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Royalty and license fee income: 300K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Enzo Biochem (NYSE: ENZ) reported Q1 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $25 million.
For earnings history and earnings-related data on Enzo Biochem (ENZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Helen of Troy rejects $37-per-share takeover bid from Spectrum Brands
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
